Weekly Recap: Pussinen named CEO and chair and EB103 advancement

What happened

Estrella Immunopharma named Cynthia Pussinen CEO and board chair, effective Oct. 25, 2026. Cheng Liu becomes chief scientific officer while remaining president and a director. Pussinen will lead corporate and clinical development, advance EB103, pursue partnerships and broaden potential applications of the ARTEMIS platform.

Confirmed

Global impact / market context

The leadership change puts corporate and clinical development under Pussinen while Liu retains the presidency and a board seat. If the stated priorities translate into progress, EB103 advancement or partnerships could affect development spending, future funding needs and the company’s ability to generate revenue.

Analyst inference

The article identifies EB103 as Estrella’s lead candidate and ARTEMIS as its platform, but gives no trial results, partnership terms, spending plans or revenue figures. Investors therefore have limited evidence here to assess whether the new leadership will change costs or commercial prospects.

Analyst inference

What to watch

1. Check whether Pussinen’s appointment takes effect on Oct. 25, 2026, and whether Liu continues as president and a director while serving as chief scientific officer. Confirmed
2. Look for company updates describing concrete EB103 development steps, since advancement may require spending on research and clinical work before any potential revenue. Analyst inference
3. Watch for disclosed partnership agreements or ARTEMIS applications; terms and scope would help show whether external collaborators could share development costs or expand the platform’s reach. Analyst inference

Evidence

• Original source link unavailable